Blackstone on Instagram: "Our portfolio company Anthos Theraputics announced groundbreaking trial data for their anti #bloodclot 🩸 treatment, abelacimab, at the @American_Heart Conference — a 67% reduction in bleeding compared to a current standard of care. Hear more from @StopTheClot and #Blackstone leaders. 👆🔊 The treatment also reduced the risk of potentially life-threatening major bleeding events by 74% and gastrointestinal bleeding by 93%. That makes abelacimab a potential game-changer f

Arizona Research Center: Clinical trials to help develop drugs to treat a variety of conditions

USC, UCLA among clinical trial team behind Leqembi, the first Alzheimer's to get full FDA approval